1. Home
  2. REGN vs ELV Comparison

REGN vs ELV Comparison

Compare REGN & ELV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • ELV
  • Stock Information
  • Founded
  • REGN 1988
  • ELV 1944
  • Country
  • REGN United States
  • ELV United States
  • Employees
  • REGN N/A
  • ELV N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • ELV Medical Specialities
  • Sector
  • REGN Health Care
  • ELV Health Care
  • Exchange
  • REGN Nasdaq
  • ELV Nasdaq
  • Market Cap
  • REGN 110.0B
  • ELV 92.9B
  • IPO Year
  • REGN 1991
  • ELV N/A
  • Fundamental
  • Price
  • REGN $701.85
  • ELV $366.09
  • Analyst Decision
  • REGN Buy
  • ELV Strong Buy
  • Analyst Count
  • REGN 24
  • ELV 14
  • Target Price
  • REGN $1,054.00
  • ELV $543.07
  • AVG Volume (30 Days)
  • REGN 920.8K
  • ELV 2.1M
  • Earning Date
  • REGN 01-31-2025
  • ELV 01-22-2025
  • Dividend Yield
  • REGN N/A
  • ELV 1.78%
  • EPS Growth
  • REGN 15.31
  • ELV 9.17
  • EPS
  • REGN 40.43
  • ELV 27.42
  • Revenue
  • REGN $13,847,100,000.00
  • ELV $174,015,000,000.00
  • Revenue This Year
  • REGN $10.20
  • ELV N/A
  • Revenue Next Year
  • REGN $4.16
  • ELV $7.57
  • P/E Ratio
  • REGN $17.36
  • ELV $13.35
  • Revenue Growth
  • REGN 5.72
  • ELV 3.20
  • 52 Week Low
  • REGN $693.00
  • ELV $362.21
  • 52 Week High
  • REGN $1,211.20
  • ELV $567.26
  • Technical
  • Relative Strength Index (RSI)
  • REGN 27.80
  • ELV 28.91
  • Support Level
  • REGN $693.00
  • ELV $362.21
  • Resistance Level
  • REGN $745.00
  • ELV $374.39
  • Average True Range (ATR)
  • REGN 21.29
  • ELV 10.65
  • MACD
  • REGN 0.05
  • ELV -1.13
  • Stochastic Oscillator
  • REGN 8.20
  • ELV 7.74

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

About ELV Elevance Health Inc.

Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.

Share on Social Networks: